C-IV

Acronym	Definition
C-IV	Schedule IV Controlled Substance (USA)

Suggest new definition

References in periodicals archive ?

- US-based pharmaceutical company Merck (NYSE: MRK) has presented results of a Phase 3 trial evaluating the efficacy and safety of Belsomra (suvorexant) C-IV for the treatment of insomnia in people with mild-to-moderate Alzheimer's disease dementia, the company said.

Merck's Belsomra C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer's Disease Dementia

United States-based Merck has revealed results of a phase three trial assessing the efficacy and safety of BELSOMRA (suvorexant) C-IV intended for the treatment of insomnia in people with mild-to-moderate Alzheimer's disease dementia, it was reported yesterday.

Merck reveals results of phase three trial of BELSOMRA (suvorexant) C-IV

HA, LN, C-IV and PIII NP were detected by using diagnostic kits.

Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients

The county has trained librarians, food bank volunteers, local pharmacy staff and others to assist people in using C-IV and kiosk applications.

An integrated approach to human services

Revised labeling including a boxed warning for Redux (dexfenfluramine hydrochloride capsules) C-IV, which is marketed by Wyeth-Ayerst, has also been submitted to the FDA because it is a related chemical compound to fenfluramine.

Wyeth-Ayerst revising 'Fen/Phen' labeling

Pharmaceutical company Dr Reddy's Laboratories (NYSE:RDY) stated on Wednesday that it has introduced its US Food & Drug Administration (USFDA) approved Eszopiclone Tablets (C-IV) 1 mg, 2 mg and 3 mg in the US market.

Dr Reddy's reports availability of FDA approved Eszopiclone tablets C-IV

Transcept Pharmaceuticals Inc awarded FDA approval of Intermezzo C-IV for middle-of-the-night insomnia

24 November 2011 - US Transcept Pharmaceuticals Inc (NASDAQ:TSPT) said on Wednesday the US Food and Drug Administration (FDA) had approved Intermezzo (zolpidem tartrate sublingual tablet) C-IV for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep.

FDA clears Transcept's Intermezzo as first insomnia drug for middle-of-the-night waking